Cantor Fitzgerald maintains UnitedHealth stock rating, sees turning point ahead

Published 30/07/2025, 16:32
Cantor Fitzgerald maintains UnitedHealth stock rating, sees turning point ahead

Investing.com - Cantor Fitzgerald has reiterated its Overweight rating for UnitedHealth Group (NYSE:UNH) with a price target of $440.00, identifying a potential turning point for the healthcare giant. The stock, currently trading near its 52-week low of $248.88, appears undervalued according to InvestingPro analysis, with a market capitalization of $235.25 billion.

The investment firm significantly reduced its 2025 earnings per share (EPS) estimate to $16.01 from $23.01, while projecting 6.7% growth to $17.09 in 2026 and 8.7% growth to $18.57 in 2027.

Cantor Fitzgerald believes UnitedHealth intentionally set conservative guidance for 2025-2027 to establish a pattern of predictable earnings with potential for exceeding expectations.

The firm expects earnings improvement in Medicare and Marketplace segments, flat margins in Optum Rx/Insight, and margin pressure in Medicaid over the coming years.

Beyond 2027, Cantor Fitzgerald anticipates UnitedHealth could achieve low-double-digit growth, potentially returning to its long-term growth range of 13-16%.

In other recent news, UnitedHealth Group has been the subject of multiple analyst updates and projections. UBS has maintained its Buy rating with a price target of $330, noting the company’s strategy to navigate Medicare Advantage challenges. Oppenheimer has lowered its price target to $325 from $400, citing UnitedHealth’s adjusted earnings per share guidance for 2025, which they believe could represent a low point before expected growth in 2026. Piper Sandler also adjusted its price target to $317 from $353, highlighting the company’s recent earnings call that provided significant transparency into its business operations. Mizuho (NYSE:MFG) maintained its Outperform rating with a $350 price target, acknowledging ongoing pricing pressures and elevated medical cost trends through 2026. Meanwhile, BofA Securities reduced its price target to $300, reflecting a slower-than-anticipated recovery pace. These developments indicate a varied analyst outlook on UnitedHealth’s financial trajectory in the coming years.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.